Medial calcification refers to mineral deposition in the middle layer of arteries. This mineralization is common in chronic kidney disease patients and causes an increased chance of cardiovascular complications. Calcitriol, the active form of vitamin D, is often administered to these patients to treat an associated condition, secondary hyperparathyroidism. Unfortunately, calcitriol treatment may promote vascular calcification due to increasing serum calcium and phosphate. We examined the effects of calcitriol supplementation on vascular smooth muscle cell (VSMC) calcification, through atomic absorption, scanning electron microscopy, and western blot analysis. Additionally, we examined the effects of the combinations of calcitriol, fibroblast growth factor 23 (FGF-23), and klotho. We determined that calcitriol supplementation alone increased calcification but was not associated with a transition towards an osteoblast-like phenotype. On the other hand, the combination of calcitriol and FGF-23 caused a decrease in calcification, but this decrease was attenuated with the further addition of klotho.
| Identifer | oai:union.ndltd.org:MSSTATE/oai:scholarsjunction.msstate.edu:td-3097 |
| Date | 11 December 2015 |
| Creators | Bennett, Kevin Andrew |
| Publisher | Scholars Junction |
| Source Sets | Mississippi State University |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | Theses and Dissertations |
Page generated in 0.0022 seconds